Navigation Links
AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
Date:8/30/2013

REDWOOD CITY, Calif., Aug. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA.  The presentation is scheduled for Wednesday, September 11, 2013 at 9:45 a.m. ET/6:45 a.m. PT.

The presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com.  For those not available to listen to the live broadcast, a replay of the presentations will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps.  Zalviso has successfully completed all three of its planned Phase 3 clinical trials and a New Drug Application submission is planned for the third quarter of 2013.  AcelRx has announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, the potential submission of an NDA for Zalviso and the timing thereof, therapeutic and commercial potential of Zalviso and the anticipated timing and therapeutic and commercial potential of other AcelRx product candidates.  These forward-looking statements are based on AcelRx's current expectations and inherently involve significant risks and uncertainties.  AcelRx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx's product development activities and clinical trials; any delays or inability to obtain, regulatory approval of its product candidates; its ability to obtain adequate clinical supplies of the drug and device components of its product candidates; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; the accuracy of AcelRx's estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the three months ended June 30, 2013, filed August 12, 2013.  AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo:  http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
2. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
3. AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
4. AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares
5. AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
6. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
7. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
8. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
9. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
10. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
11. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
(Date:2/23/2017)... 2017 Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet ... der südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von ... an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO ... year. Dyer started as the Chairman of the Management Committee when IFN was ... corporation including the recruitment of investor/owners and development of the business plan. He ...
(Date:2/23/2017)... ... 2017 , ... Thinksport, the most award-winning sunscreen on the ... Marin. For the second year in a row, cyclists will stay protected from ... thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts again ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial ... 74th Annual Meeting. KLS is a longtime supporter of the event. , "We ... and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... “Doping in Sport: How the Culture Might Change,” in conjunction with ... symposium will be held at Pepperdine University in Malibu, California. , Sir Philip ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):